Biotech Startups

RNAV8 Bio develops a toolkit for engineering mRNA therapeutics, optimizing non-coding sequences to improve expression and efficacy of mRNA-based treatments. The company serves pharmaceutical and biotech organizations seeking to expand the clinical application of mRNA technology.

5 investors

Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders. The company creates potentially curative treatments at the genetic level for inherited and rare diseases.

5 investors

RoosterBio supplies human mesenchymal stem/stromal cells (hMSCs), exosome systems, and cGMP media with built-in processes and protocols for companies and researchers developing cell therapy, gene therapy, and tissue engineering products. Its scalable bioprocessing solutions are used by government, academic, and industry partners to move therapeutic technologies from research through clinical manufacturing.

5 investors

Rx Redefined provides a platform and management services for DMEPOS (durable medical equipment, prosthetics, orthotics, and supplies) ordering, handling revenue cycle processes, compliance checks, and audit processing for physicians. It integrates with existing EMR systems and reviews billing requirements, patient eligibility, and regulatory adherence for each physician order.

5 investors

Ryght AI provides an artificial intelligence-powered platform that uses digital twin technology to help clinical research organizations and sponsors identify and select optimal sites for clinical trials. The platform analyzes thousands of global research sites to compress traditional site selection timelines from months to weeks while reducing costs and improving enrollment outcomes.

5 investors

Samsara Therapeutics develops small-molecule therapeutics that activate autophagy to slow the progression of age-related neurodegenerative diseases such as ALS, Parkinson's, and Charcot-Marie-Tooth disease. It runs an in-house phenotypic screening platform using patient-derived iPSCs to identify and validate autophagy activators for drug discovery.

5 investors

CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease. It operates through its CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor businesses.

5 investors

Sano provides a platform combining genetic testing, patient recruitment, and engagement tools for precision medicine clinical trials. The platform helps research teams enroll participants and manage operations more efficiently in precision medicine studies.

5 investors

Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations. The company uses its proprietary Cell-seq platform to develop small molecule programs for genetic disorders.

5 investors

Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine. The company serves the clinical research and pharmaceutical industry.

5 investors

Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals. The company was acquired by animal health firm Ceva in early 2024, and its work now operates as Ceva's biotechnology campus in Philadelphia.

5 investors

Seismic Therapeutic is a clinical-stage biotechnology company that uses machine learning to discover and develop immunology therapies for autoimmune diseases. The company develops a pipeline of biologics derived from its IMPACT platform to control dysregulated adaptive immunity.

5 investors

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

5 investors

Seneca Therapeutics develops oncolytic virus immunotherapies, particularly Seneca Valley Virus (SVV-001), for treating aggressive and therapy-resistant solid cancers. The company's pipeline includes both monotherapy and gene-armed viral approaches targeting multiple cancer indications, with an IND application open to begin clinical trials in early 2025.

5 investors

Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.

5 investors

Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.

5 investors

Shiok Meats is a cell-based meat company focused on seafood, using cellular agriculture to grow shrimp and other seafood from cells in a laboratory rather than from animals. It is the first cell-based meat company in Singapore and Southeast Asia.

5 investors

A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

5 investors

Solar Foods produces Solein, a sustainable protein ingredient created through gas fermentation technology that converts CO2 and renewable electricity into edible protein. The company targets food brands and the health & performance nutrition market seeking alternatives to conventional animal and plant proteins.

5 investors

Cellular Intelligence is a cell therapy company developing engineered cell treatments for diseases, including a Phase 2-ready therapy for Parkinson's disease acquired from Novo Nordisk. The company applies computational biology and synthetic biology approaches to reprogram cellular function.

5 investors

Sparxell designs, engineers, and manufactures plant-based colorants using cellulose, including biomimetic pigments, biodegradable glitter, powders, pearls, foils, and specialty shapes such as sequins. Its products are aimed at high-end consumer product applications, offering an alternative to synthetic dyes, mica, and titania.

5 investors

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.

5 investors

Pharma Edge is an investment portfolio focused on equity securities of pharmaceutical and healthcare companies, targeting both the US and Indian markets to capitalize on rising healthcare demand and patent expirations. The portfolio invests across pharmaceutical companies, biotech firms, healthcare services, and insurance sectors.

5 investors

AbbVie is a pharmaceutical company that discovers and develops medicines, working with external innovation partners to conduct research. It operates in the biopharmaceutical industry.

5 investors